<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627103</url>
  </required_header>
  <id_info>
    <org_study_id>GIW 20-001</org_study_id>
    <nct_id>NCT04627103</nct_id>
  </id_info>
  <brief_title>Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Trial for a Procedure for Duodenal-Ileal Diversion With a Sleeve Gastrectomy for Patients With Obesity and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GI Windows, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GI Windows, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study will monitor weight loss and metabolic indicators for subjects in multi-center, single&#xD;
      arm trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-Center, Open-label Pilot Study to Evaluate the Safety and Effectiveness of the GI&#xD;
      Windows Single Neodymium Magnet Anastomosis Procedure When Used to Create a Duodenal-Ileal&#xD;
      Diversion with a Sleeve Gastrectomy (SNAP-S) for Subjects with Obesity and Type 2 Diabetes&#xD;
      Mellitus (T2DM)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 7, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 7, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>12 months</time_frame>
    <description>Weight loss measured as a percent of total body weight (TBW)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Responders</measure>
    <time_frame>12 months</time_frame>
    <description>Percent responders; i.e. percent of subjects losing at least 10% TBW</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excess Weight Loss Measures</measure>
    <time_frame>12 months</time_frame>
    <description>Excess weight loss (EWL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Weight Loss Measures</measure>
    <time_frame>12 months</time_frame>
    <description>Absolute weight loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI - Weight Loss Measures</measure>
    <time_frame>12 months</time_frame>
    <description>Change in BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Glucose</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in Hemoglobin A1c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Remission and/or Improvements</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects experiencing diabetes remission and/or improvements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diabetes Medication Dosage and Frequency Changes</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in the dosage and frequency of diabetes medications from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Lipids</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change in serum lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure Changes</measure>
    <time_frame>12 months</time_frame>
    <description>Mean percent change in systolic/diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver Changes using Fibroscan</measure>
    <time_frame>12 months</time_frame>
    <description>Change in Controlled Attenuation Parameter (CAP) Scores from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional Status</measure>
    <time_frame>12 months</time_frame>
    <description>Nutritional Status: changes in pre-albumin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin - Nutritional Status</measure>
    <time_frame>12 months</time_frame>
    <description>Nutritional Status: changes in albumin levels</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Device Placement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects in this arm will receive the Self-Forming Magnet (SFM) System that will be used to create a duodenal-ileal diversion. Following the diversion creation, a sleeve gastrectomy will also be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Self Forming Magnetic (SFM) Anastomosis System</intervention_name>
    <description>The SFM will be placed using an endoscope in the duodenum and laparoscopically into the ileum. A compression anastomosis will be created in each of the subjects and the diversion of enteral flow from the duodenum to ileum will create a metabolic effect that will induce weight loss and impact Type 2 Diabetes. Following the diversion being created, a gastric sleeve will be created according to standard technique.</description>
    <arm_group_label>Device Placement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 19-65 years at screening&#xD;
&#xD;
          -  Body mass index (BMI) ≥35 and ≤50&#xD;
&#xD;
          -  T2DM diagnosis ≥6 months but &lt; 10 years, with 1 or more oral diabetes medications,&#xD;
             HbA1c ≥ 6.5% but &lt; 10.0% at time of enrollment.&#xD;
&#xD;
          -  HbA1c must be stable over a 3-month period.&#xD;
&#xD;
          -  Weight stable over 3-month period&#xD;
&#xD;
          -  Obesity-related comorbidities (hypertension, dyslipidemia, sleep apnea) must be&#xD;
             well-controlled&#xD;
&#xD;
          -  Agrees to refrain from any type of additional bariatric or reconstructive surgery that&#xD;
             would affect body weight for a duration of 2 years&#xD;
&#xD;
          -  If female, subject must commit to not becoming pregnant for 24 months and agree to use&#xD;
             contraception during this period&#xD;
&#xD;
          -  Able to understand and sign informed consent documents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected allergy to nickel or titanium or nitinol&#xD;
&#xD;
          -  Type 1 diabetes or poorly controlled type 2 diabetes&#xD;
&#xD;
          -  Use of injectable insulin&#xD;
&#xD;
          -  Any documented conditions for which endoscopy would be contraindicated&#xD;
&#xD;
          -  Contraindication to general anesthesia&#xD;
&#xD;
          -  History of chronic gastrointestinal disease&#xD;
&#xD;
          -  Congenial or acquired anomalies of the GI tract&#xD;
&#xD;
          -  Any previous major surgery on the stomach, duodenum, hepatobiliary tree (excluding&#xD;
             gallbladder), pancreas, or right colon.&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Pre-existing severe comorbid cardio-respiratory disease&#xD;
&#xD;
          -  History of chronic gastrointestinal disease&#xD;
&#xD;
          -  Specific genetic or hormonal cause of obesity&#xD;
&#xD;
          -  Recent tobacco/nicotine product cessation (within 3 months prior)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Peter J Lukin</last_name>
    <phone>9787610183</phone>
    <email>peter.lukin@giwindows.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Ellsmere, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Biertho, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Metabolic Disease</keyword>
  <keyword>Sleeve Gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

